S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
Log in

NASDAQ:CHRS - Coherus Biosciences Stock Price, Forecast & News

$19.19
-1.19 (-5.84 %)
(As of 02/27/2020 04:00 PM ET)
Today's Range
$19.11
Now: $19.19
$20.19
50-Day Range
$17.39
MA: $19.85
$22.53
52-Week Range
$12.95
Now: $19.19
$23.91
Volume1.21 million shs
Average Volume1.10 million shs
Market Capitalization$1.35 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.16
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CHRS
CUSIPN/A
Phone650-649-3530

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.56 million
Book Value($0.57) per share

Profitability

Net Income$-209,340,000.00

Miscellaneous

Employees232
Market Cap$1.35 billion
Next Earnings Date2/27/2020 (Confirmed)
OptionableOptionable

Receive CHRS News and Ratings via Email

Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.


Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions

What is Coherus Biosciences' stock symbol?

Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."

How were Coherus Biosciences' earnings last quarter?

Coherus Biosciences Inc (NASDAQ:CHRS) issued its earnings results on Wednesday, November, 6th. The biotechnology company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.36 by $0.27. The biotechnology company had revenue of $111.68 million for the quarter, compared to the consensus estimate of $93.58 million. View Coherus Biosciences' Earnings History.

When is Coherus Biosciences' next earnings date?

Coherus Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Coherus Biosciences.

What price target have analysts set for CHRS?

7 brokerages have issued 12 month price targets for Coherus Biosciences' shares. Their forecasts range from $27.00 to $43.00. On average, they anticipate Coherus Biosciences' stock price to reach $32.71 in the next twelve months. This suggests a possible upside of 70.5% from the stock's current price. View Analyst Price Targets for Coherus Biosciences.

What is the consensus analysts' recommendation for Coherus Biosciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Coherus Biosciences.

Has Coherus Biosciences been receiving favorable news coverage?

News headlines about CHRS stock have trended somewhat negative on Thursday, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Coherus Biosciences earned a coverage optimism score of -1.7 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Coherus Biosciences.

Are investors shorting Coherus Biosciences?

Coherus Biosciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 10,770,000 shares, an increase of 7.2% from the January 15th total of 10,050,000 shares. Based on an average daily volume of 1,040,000 shares, the days-to-cover ratio is currently 10.4 days. Currently, 16.9% of the company's stock are short sold. View Coherus Biosciences' Current Options Chain.

Who are some of Coherus Biosciences' key competitors?

What other stocks do shareholders of Coherus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus Biosciences investors own include Chembio Diagnostics (CEMI), Halozyme Therapeutics (HALO), Intelsat (I), Exelixis (EXEL), Bank of America (BAC), Heron Therapeutics (HRTX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Fossil Group (FOSL) and Sangamo Therapeutics (SGMO).

Who are Coherus Biosciences' key executives?

Coherus Biosciences' management team includes the folowing people:
  • Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 64)
  • Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 53)
  • Dr. Peter K. Watler, Chief Technical Officer (Age 57)
  • Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Supervisory Board (Age 67)
  • Mr. Vincent R. Anicetti, Chief Operating Officer (Age 64)

Who are Coherus Biosciences' major shareholders?

Coherus Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Temasek Holdings Private Ltd (10.53%), State Street Corp (4.97%), Lord Abbett & CO. LLC (4.38%), Alliancebernstein L.P. (3.11%), UBS Asset Management Americas Inc. (2.73%) and Goldman Sachs Group Inc. (2.02%). Company insiders that own Coherus Biosciences stock include Barbara K Finck, Dennis M Lanfear, James Healy, Jean-Frederic Viret and Vincent R Anicetti. View Institutional Ownership Trends for Coherus Biosciences.

Which major investors are selling Coherus Biosciences stock?

CHRS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Partner Fund Management L.P., First Trust Advisors LP, Chartwell Investment Partners LLC, Credit Suisse AG, 361 Capital LLC, PNC Financial Services Group Inc. and Russell Investments Group Ltd.. Company insiders that have sold Coherus Biosciences company stock in the last year include Dennis M Lanfear, James Healy, Jean-Frederic Viret and Vincent R Anicetti. View Insider Buying and Selling for Coherus Biosciences.

Which major investors are buying Coherus Biosciences stock?

CHRS stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Temasek Holdings Private Ltd, State Street Corp, Hawk Ridge Capital Management LP, Goldman Sachs Group Inc., UBS Asset Management Americas Inc., Charles Schwab Investment Management Inc. and Panagora Asset Management Inc.. View Insider Buying and Selling for Coherus Biosciences.

How do I buy shares of Coherus Biosciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Coherus Biosciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $19.19.

How big of a company is Coherus Biosciences?

Coherus Biosciences has a market capitalization of $1.35 billion and generates $1.56 million in revenue each year. The biotechnology company earns $-209,340,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe.View Additional Information About Coherus Biosciences.

What is Coherus Biosciences' official website?

The official website for Coherus Biosciences is http://www.coherus.com/.

How can I contact Coherus Biosciences?

Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]


MarketBeat Community Rating for Coherus Biosciences (NASDAQ CHRS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  367 (Vote Outperform)
Underperform Votes:  353 (Vote Underperform)
Total Votes:  720
MarketBeat's community ratings are surveys of what our community members think about Coherus Biosciences and other stocks. Vote "Outperform" if you believe CHRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel